Bone morphogenetic protein-16 (bmp-16) compositions
CA 2265508 C · Owner: Genetics Institute, Llc · Inventors: Celeste, Anthony J.; Murray, Beth L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Purified BMP-16 proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-16 proteins are also disclosed. The proteins may be used in the treatment of bone, cartilage other connective tissue defects and , disorders including tendon, ligament and meniscus in wound healing and , related tissue repair as well as for treatment of disorders and defects to tissues which include epidermis, nerve muscle, including cardiac muscle, and other tissues and wounds, and organs such as liver lung, cardiac, pancreas , and kidney tissue. The proteins may also be useful for the induction of growth and/or differentiation of undifferentiated embryonic and stem cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 9, 1997 and granted November 18, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 9, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 9, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.